search
Back to results

Effect of Timed-Restricted Eating on Metabolic Health (TREAT)

Primary Purpose

Obesity, Non-Alcoholic Fatty Liver Disease, Insulin Resistance

Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Early time restricted eating
Late time restricted eating
Sponsored by
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity

Eligibility Criteria

50 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Ability to provide informed consent; BMI > 30kg/m^2; Insulin resistance, as defined by fasting plasma insulin > 62 pmol/L and/or prediabetes, as defined by fasting plasma glucose > 5.3 and < 7.0 mmol/L; Stable weight for 3 months prior to study inclusion For women, 1 year after last menstrual cycle Exclusion Criteria: Use of any medication, except for those related to treatment of metabolic syndrome; Any medical condition interfering with study outcomes or design; History of any psychiatric disorder, including eating disorders; Performing shift work Performing intensive sports (>3 hours/week); Smoking; Drugs abuse or alcohol abuse (>3 units/day); Contraindication for MRI; Known lactose/gluten intolerance; Known soy, egg, milk or peanut allergy; Childhood onset of obesity

Sites / Locations

  • Amsterdam UMC, location AMCRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Early time-restricted eating

Late time-restricted eating

Arm Description

50% of daily calories at breakfast, 35% at lunch and 15% at dinner. 85% of calories consumed in 6h, i.e., between 7AM and 1PM. Eating period, 10h (7AM-5PM); fasting period, 14h; Breakfast between 7 and 8 AM; lunch between 12 AM and 1 PM; dinner between 4 and 5 PM.

15% of daily calories at breakfast, 35% at lunch and 50% at dinner. 85% of calories consumed in 6h, i.e., between 2PM and 8PM. Eating period, 10h (10AM-8PM), fasting period, 14h; Breakfast between 10 and 11 AM; lunch between 2 and 3 PM; dinner between 7 and 8 PM.

Outcomes

Primary Outcome Measures

Insulin Sensitivity
We will use the Oral Minimal Model Method in conjunction with a Mixed Meal Tolerance Test (MMTT) to quantitatively evaluate insulin sensitivity. Concentrations of insulin, glucose, and C-peptide will be measured during the course of the MMTT to serve as the requisite inputs for the model. The output is in dl/kg/min/uU/ml.

Secondary Outcome Measures

Change in plasma insulin
Fasted and stimulated insulin (pmol/L) will be measured during MMTT
Change in plasma glucose
Fasted and stimulated glucose (mmol/L) will be measured during MMTT
Change in intrahepatic fat
To quantify the intrahepatic fat content, a single voxel 1H-MRS (magnetic resonance spectroscopy) will be used. Relative fat content will be expressed as the ratio of the fat peak over the cumulative fat and water peak. This will also be corrected for T2 relaxation.
Change in beta cell function (C-peptide)
Fasted and stimulated C-peptide (nmol/L) will be measured during MMTT
Change in insulin aignaling
Biopsies will be taken from skeletal muscle and subcutaneous fat to measure key proteins in the insulin signalling pathway (Western blots)
Change in glucose variability
In our study, we will deploy Continuous Glucose Monitors (CGMs) to acquire an in-depth understanding of glucose variability in participants throughout the course of the intervention. These monitors gauge glucose concentrations in the interstitial fluid (mmol/L), serving as a reliable proxy for blood glucose levels. This approach will enable us to assess key metrics such as mean, minimum and maximum glucose levels.
De novo lipogenesis
Fasted and stimulated de novo lipogenesis (DNL) will be measured during the MMT as 2H incorporation into fatty acids following deuterated water (2H2O) administration
Immunological markers
We will conduct immune cell phenotyping on whole blood samples to identify and categorize various immune cell types. Additionally, we will assess immune cell function and metabolism in isolated peripheral blood mononuclear cells (PBMCs). Inflammatory markers will also be assessed in serum samples to provide a comprehensive overview of immune and inflammatory status.
Physical activity
Physical activity will be assessed via accelerometry. Accelerometry represents the magnitude of acceleration in any direction, over a predefined epoch.
Functional brain activity
Brain activation maps and functional connectivity will be assessed by blood oxygen dependent signals in the resting state and after visual food cues using functional magnetic resonance imaging (fMRI).
Psychological factor - Food Craving
We will use the General Food Cravings Questionnaire (G-FCQ) to evaluate the frequency and intensity of food cravings among participants. The scoring for the G-FCQ ranges between 21 and 105, with higher scores indicative of more pronounced food craving tendencies.
Psychological factor - Eating behaviour
We will utilize the Dutch Eating Behavior Questionnaire (NVE) to assess and categorize the eating behaviors and tendencies of our participants. The NVE discerns three distinct eating styles: emotional eating, external eating, and restrained eating. A higher score within a specific style suggests a predominant inclination towards that particular eating behavior.
Psychological factor - Hunger scale
We will employ a nine-question visual analogue scale (VAS) to assess hunger. Each question will be scored 0-100.
Psychological factor - Food addiction
We will use the Yale Food Addiction Scale 2.0 (YFAS 2.0) to assess addictive behaviours. The YFAS 2.0 is designed in accordance with the DSM-5 criteria, and its scoring system mirrors the number of DSM-5 criteria fulfilled indicative of addiction.
Psychological factor - Impulsiveness
We will use the Barratt Impulsiveness Scale (BIS) to scale impulsiveness towards food. This will help us understand how impulsivity might influence dietary behaviour. The score ranges from 30-120 and a higher score leans towards greater impulsivity.
Psychological factor - Chronotype
To determine natural sleep-wake patterns, we will use the Munich Chronotype Questionnaire (MCTQ). This tool offers a comprehensive understanding of sleep behaviors, revealing a chronotype.
Subject experience with intervention
We will employ a semi-structured oral interview as part of our qualitative approach to understand our participants' experience and adherence to the intervention.
Delay discounting computational task
The delay discounting task aids in understanding the decision-making processes that might contribute to overeating and poor food choices. In this task, we will be able to measure the ability of each individual to delay immediate gratification for a greater future reward.
Iowa gambling computational task
We use the Iowa gambling task to assess decision-making and risk-reward sensitivity. Participants choose cards from four decks, each with different reward and punishment rates, aiming to maximize their winnings. We use this task to study risk taking and impulsive behaviour.

Full Information

First Posted
September 24, 2023
Last Updated
September 24, 2023
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators
Diabetesfonds
search

1. Study Identification

Unique Protocol Identification Number
NCT06061042
Brief Title
Effect of Timed-Restricted Eating on Metabolic Health
Acronym
TREAT
Official Title
The Effect of Timed-Restricted Eating on Insulin Sensitivity, De Novo Lipogenesis and Liver Fat in Subjects With Obesity and Insulin Resistance
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 2023 (Anticipated)
Primary Completion Date
December 2027 (Anticipated)
Study Completion Date
December 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators
Diabetesfonds

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
We aim to determine the effect of combined isocaloric time restricted eating and meal timing on metabolic health, liver fat, functional brain networks, inflammation, and sleep pattern/quality in subjects with obesity and insulin resistance.
Detailed Description
Obesity is an alarming global health issue, with increasing prevalence. Obesity leads to a vast array of disorders, including dyslipidemia, the accumulation of intrahepatic triglycerides (IHTG), multiorgan insulin resistance and type 2 diabetes mellitus. In addition, disruption of the circadian rhythm (circadian misalignment), which is associated with irregular eating schedules, is an important risk factor for the development of obesity, IHTG and type 2 diabetes mellitus. Time restricted eating (TRE) is a form of intermittent fasting, in which the daily eating period is restricted. The beneficial effect of this type of diet might relate to adequate synchronization of food intake and fasting to the internal rhythm of the circadian tissue clocks, improving metabolic handling of nutrients and metabolic flexibility.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Non-Alcoholic Fatty Liver Disease, Insulin Resistance

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Early time-restricted eating
Arm Type
Experimental
Arm Description
50% of daily calories at breakfast, 35% at lunch and 15% at dinner. 85% of calories consumed in 6h, i.e., between 7AM and 1PM. Eating period, 10h (7AM-5PM); fasting period, 14h; Breakfast between 7 and 8 AM; lunch between 12 AM and 1 PM; dinner between 4 and 5 PM.
Arm Title
Late time-restricted eating
Arm Type
Experimental
Arm Description
15% of daily calories at breakfast, 35% at lunch and 50% at dinner. 85% of calories consumed in 6h, i.e., between 2PM and 8PM. Eating period, 10h (10AM-8PM), fasting period, 14h; Breakfast between 10 and 11 AM; lunch between 2 and 3 PM; dinner between 7 and 8 PM.
Intervention Type
Behavioral
Intervention Name(s)
Early time restricted eating
Other Intervention Name(s)
early-TRE
Intervention Description
Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the early-TRE group is between 7 AM - 5 PM
Intervention Type
Behavioral
Intervention Name(s)
Late time restricted eating
Other Intervention Name(s)
late-TRE
Intervention Description
Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the late-TRE group is between 10 AM - 8 PM
Primary Outcome Measure Information:
Title
Insulin Sensitivity
Description
We will use the Oral Minimal Model Method in conjunction with a Mixed Meal Tolerance Test (MMTT) to quantitatively evaluate insulin sensitivity. Concentrations of insulin, glucose, and C-peptide will be measured during the course of the MMTT to serve as the requisite inputs for the model. The output is in dl/kg/min/uU/ml.
Time Frame
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Secondary Outcome Measure Information:
Title
Change in plasma insulin
Description
Fasted and stimulated insulin (pmol/L) will be measured during MMTT
Time Frame
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Title
Change in plasma glucose
Description
Fasted and stimulated glucose (mmol/L) will be measured during MMTT
Time Frame
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Title
Change in intrahepatic fat
Description
To quantify the intrahepatic fat content, a single voxel 1H-MRS (magnetic resonance spectroscopy) will be used. Relative fat content will be expressed as the ratio of the fat peak over the cumulative fat and water peak. This will also be corrected for T2 relaxation.
Time Frame
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Title
Change in beta cell function (C-peptide)
Description
Fasted and stimulated C-peptide (nmol/L) will be measured during MMTT
Time Frame
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Title
Change in insulin aignaling
Description
Biopsies will be taken from skeletal muscle and subcutaneous fat to measure key proteins in the insulin signalling pathway (Western blots)
Time Frame
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Title
Change in glucose variability
Description
In our study, we will deploy Continuous Glucose Monitors (CGMs) to acquire an in-depth understanding of glucose variability in participants throughout the course of the intervention. These monitors gauge glucose concentrations in the interstitial fluid (mmol/L), serving as a reliable proxy for blood glucose levels. This approach will enable us to assess key metrics such as mean, minimum and maximum glucose levels.
Time Frame
Baseline 1 to week 4 for intervention 1, Baseline 2 to week 12 for intervention 2
Title
De novo lipogenesis
Description
Fasted and stimulated de novo lipogenesis (DNL) will be measured during the MMT as 2H incorporation into fatty acids following deuterated water (2H2O) administration
Time Frame
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Title
Immunological markers
Description
We will conduct immune cell phenotyping on whole blood samples to identify and categorize various immune cell types. Additionally, we will assess immune cell function and metabolism in isolated peripheral blood mononuclear cells (PBMCs). Inflammatory markers will also be assessed in serum samples to provide a comprehensive overview of immune and inflammatory status.
Time Frame
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Title
Physical activity
Description
Physical activity will be assessed via accelerometry. Accelerometry represents the magnitude of acceleration in any direction, over a predefined epoch.
Time Frame
Baseline 1 to week 4 for intervention 1, Baseline 2 to week 12 for intervention 2
Title
Functional brain activity
Description
Brain activation maps and functional connectivity will be assessed by blood oxygen dependent signals in the resting state and after visual food cues using functional magnetic resonance imaging (fMRI).
Time Frame
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Title
Psychological factor - Food Craving
Description
We will use the General Food Cravings Questionnaire (G-FCQ) to evaluate the frequency and intensity of food cravings among participants. The scoring for the G-FCQ ranges between 21 and 105, with higher scores indicative of more pronounced food craving tendencies.
Time Frame
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Title
Psychological factor - Eating behaviour
Description
We will utilize the Dutch Eating Behavior Questionnaire (NVE) to assess and categorize the eating behaviors and tendencies of our participants. The NVE discerns three distinct eating styles: emotional eating, external eating, and restrained eating. A higher score within a specific style suggests a predominant inclination towards that particular eating behavior.
Time Frame
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Title
Psychological factor - Hunger scale
Description
We will employ a nine-question visual analogue scale (VAS) to assess hunger. Each question will be scored 0-100.
Time Frame
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Title
Psychological factor - Food addiction
Description
We will use the Yale Food Addiction Scale 2.0 (YFAS 2.0) to assess addictive behaviours. The YFAS 2.0 is designed in accordance with the DSM-5 criteria, and its scoring system mirrors the number of DSM-5 criteria fulfilled indicative of addiction.
Time Frame
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Title
Psychological factor - Impulsiveness
Description
We will use the Barratt Impulsiveness Scale (BIS) to scale impulsiveness towards food. This will help us understand how impulsivity might influence dietary behaviour. The score ranges from 30-120 and a higher score leans towards greater impulsivity.
Time Frame
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Title
Psychological factor - Chronotype
Description
To determine natural sleep-wake patterns, we will use the Munich Chronotype Questionnaire (MCTQ). This tool offers a comprehensive understanding of sleep behaviors, revealing a chronotype.
Time Frame
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Title
Subject experience with intervention
Description
We will employ a semi-structured oral interview as part of our qualitative approach to understand our participants' experience and adherence to the intervention.
Time Frame
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Title
Delay discounting computational task
Description
The delay discounting task aids in understanding the decision-making processes that might contribute to overeating and poor food choices. In this task, we will be able to measure the ability of each individual to delay immediate gratification for a greater future reward.
Time Frame
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
Title
Iowa gambling computational task
Description
We use the Iowa gambling task to assess decision-making and risk-reward sensitivity. Participants choose cards from four decks, each with different reward and punishment rates, aiming to maximize their winnings. We use this task to study risk taking and impulsive behaviour.
Time Frame
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Ability to provide informed consent; BMI > 30kg/m^2; Insulin resistance, as defined by fasting plasma insulin > 62 pmol/L and/or prediabetes, as defined by fasting plasma glucose > 5.3 and < 7.0 mmol/L; Stable weight for 3 months prior to study inclusion For women, 1 year after last menstrual cycle Exclusion Criteria: Use of any medication, except for those related to treatment of metabolic syndrome; Any medical condition interfering with study outcomes or design; History of any psychiatric disorder, including eating disorders; Performing shift work Performing intensive sports (>3 hours/week); Smoking; Drugs abuse or alcohol abuse (>3 units/day); Contraindication for MRI; Known lactose/gluten intolerance; Known soy, egg, milk or peanut allergy; Childhood onset of obesity
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jur Kroon, BSc
Phone
+31 683238752
Email
jur.kroon@amsterdamumc.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Sarah E Siegelaar, MD PhD
Email
s.e.siegelaar@amsterdamumc.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mireille JM Serlie, MD PhD
Organizational Affiliation
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Amsterdam UMC, location AMC
City
Amsterdam
State/Province
Noord-Holland
ZIP/Postal Code
1105AZ
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jur Kroon, BSc
Phone
+31 683238752
Email
jur.kroon@amsterdamumc.nl
First Name & Middle Initial & Last Name & Degree
Jur Kroon, BSc

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effect of Timed-Restricted Eating on Metabolic Health

We'll reach out to this number within 24 hrs